A PHD inhibitor prevents changes in the phosphoproteome and capillary rarefaction by CsA: treatment option for CKD?

Labes et al. analyze the phosphoproteome in a mouse model of chronic cyclosporine A nephrotoxicity and detect significant changes in the angiogenic pathway. Furthermore, they observe reduced hemoglobin levels and capillary rarefaction in the kidney. The authors show that coadministration of the hypoxia-inducible factor prolyl hydroxylase inhibitor daprodustat almost completely prevents changes of the phosphoproteome and capillary rarefaction, suggesting that prolyl hydroxylase domain enzyme inhibitors may preserve microvasculature of the kidney, which is commonly impaired in chronic kidney disease.

Automated summary

Labes et al. analyzed the phosphoproteome in a mouse model of chronic cyclosporine A nephrotoxicity and found significant changes in the angiogenic pathway. By coadministering the hypoxia-inducible factor prolyl hydroxylase inhibitor daprodustat, they were able to almost completely prevent these changes and preserve the microvasculature of the kidney.